Altre lingue BioLineRx Ltd.

Azioni

BLRX

IL0011015182

Biotecnologia

Mercato chiuso - TEL AVIV STOCK EXCHANGE Altri mercati azionari 16:24:04 16/04/2026			Variaz. 5gg	Var. 1 gen.
1,300 ^ILa	0,00%		0,00%	-18,75%

26/03	BioLineRx annuncia l'avvio dello studio di Fase 1/2a su GLIX1 per il trattamento del glioblastoma (GBM)	CI
23/03	BioLineRx Ltd. annuncia i risultati finanziari per l'esercizio chiuso al 31 dicembre 2025	CI

Altre lingue

08/04	La historia de la semana: ¿Por qué el mercado bursátil israelí resiste tan bien?
26/03	BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma
23/03	BioLineRx Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025
23/03	BioLineRx Reports 2025 Financial Results and Provides Corporate Update
23/03	BioLineRx Ltd. Auditor Raises 'Going Concern' Doubt
24/11	BioLineRx : Consolidated Financial Statements as of September 30, 2025
24/11	BioLineRx Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
24/11	BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
18/11	BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
17/11	BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
29/09/25	BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
29/09/25	Biolinerx Ltd. and Hemispherian as Establish Joint Venture to Develop Glix1, A First-In-Class, Oral, Small Molecule Targeting Dna Damage Response in Glioblastoma and Other Cancers
14/08/25	BioLineRx Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
14/08/25	BioLineRx : Consolidated Financial Statements as of June 30, 2025
14/08/25	Biolinerx reports second quarter financial results
14/08/25	BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
07/08/25	BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
23/06/25	BioLineRx : Consolidated Financial Statements as of September 30, 2024
20/06/25	BioLineRx : Consolidated Financial Statements as of June 30, 2024
20/06/25	BioLineRx : Consolidated Financial Statements as of March 31, 2025
30/05/25	Top Midday Gainers
30/05/25	BioLineRx To Present New Pilot Phase Data From Phase 2 Combination Trial Of Motixafortide At ASCO 2025 Annual Meeting
30/05/25	BioLineRx Ltd. Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer to Be Presented at ASCO 2025 Annual Meeting
30/05/25	Bioline Says Pilot Study of Potential Pancreatic Cancer Drug Combo Shows Improved Overall Response Rate; Shares Soar Pre-Bell
30/05/25	Top Premarket Gainers